JAFKX Mutual Fund

NAV$20.64

Fund Essentials - as of Dec 31, 2025

Net Assets
-
Expense Ratio
1.24%
Dividend Yield (Current)
15.85%
Holdings
171
Inception Date
Jan 28, 2002
Fund Family
John Hancock
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Annually

Performance

YTD+8.40%
1 Year+31.91%

Asset Allocation

Stocks: 99.68%
Other: 0.32%

Price Chart (6M)

View Full Chart →

Top Holdings

View All →
TickerNameWeight
LLYEli Lilly & Co12.36%
ISRGIntuitive Surg4.49%
TMOThermo Fisher4.28%
ARGX:ASArgenx Se Spon Adr Each Rep 1 Ord Shs3.94%
SYKStryker Corp3.54%
Top 10 Concentration: 42.96%Report Date: Dec 31, 2025
Download all 171 holdings for JAFKX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
15.85%
Frequency
Annually

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

JAFKX Mutual Fund Overview

JAFKX Mutual Fund (John Hancock Variable Insurance Trust Health Sciences Trust Series II) is managed by John Hancock. JAFKX expense ratio is 1.24%, holding 171 positions across sectors including Health Care, Unknown, Financials. Inception date: 2002-01-28.

JAFKX performance shows a YTD return of 8.40%. The 1-year return is 31.91%. JAFKX dividend yield stands at 15.85%, paid annually.

JAFKX top holdings include Eli Lilly & Co (12.4%), Intuitive Surg (4.5%), Thermo Fisher (4.3%), Argenx Se Spon Adr Each Rep 1 Ord Shs (3.9%), Stryker Corp (3.5%). View all JAFKX holdings, sector breakdown, or dividend history.

JAFKX can be compared against other funds using the overlap calculator or side-by-side comparison tool. JAFKX alternatives are available via the screener, along with tax-loss harvesting opportunities.